Chunlong Zhao

Chunlong Zhao

Auto-generated profile, based on publicly available information

Chunlong Zhao

Department of Chemical and Pharmaceutical Biology, Groningen, Research Institute of Pharmacy (GRIP) University of Groningen Antonius Deusinglaan 1 9713 AV Groningen The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
CZChunlong Zhao
Chunlong Zhao
SCShipeng Chen
Shipeng Chen
DCDENG CHEN
DENG CHEN
CRClàudia Río‐Bergé
Clàudia Río‐Bergé
JZJianqiu Zhang
Jianqiu Zhang
Frank DekkerFrank Dekker
Frank Dekker
Macrophage polarization plays a crucial role in inflammatory processes. The histone deacetylase 3 (HDAC3) has a deacetylase‐independent function that can activate pro‐inflammatory gene expression in lipopolysaccharide‐stimulated M1‐like macrophages and cannot be blocked by traditional small‐molecule HDAC3 inhibitors. Here we employed the proteolysis targeting chimera (PROTAC) technology to target the deacetylase‐independent function of HDAC3. We developed a potent and selective HDAC3‐directed PROTAC, P7, which induces nearly complete HDAC3 degradation at low micromolar concentrations in both THP‐1 cells and human primary macrophages. P7 increases the anti‐inflammatory cytokine secretion in THP‐1‐derived M1‐like macrophages. Importantly, P7 decreases the secretion of pro‐inflammatory cytokines in M1‐like macrophages derived from human primary macrophages. This can be explained by the observed inhibition of macrophage polarization from M0‐like into M1‐like macrophage. In conclusion, we demonstrate that the HDAC3‐directed PROTAC P7 has anti‐inflammatory activity and blocks macrophage polarization, demonstrating that this molecular mechanism can be targeted with small molecule therapeutics.

5 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CZChunlong Zhao
Chunlong Zhao
YZYu Zhang
Yu Zhang
JZJin’gE Zhang
Jin’gE Zhang
SLShunda Li
Shunda Li
MLMengyang Liu
Mengyang Liu
YZYingjie Zhang
Yingjie Zhang

27 January 2025 in European Journal of Cancer
Verified
Journal Article
Open access
JSJosephine Strijker
Josephine Strijker
GPGuillem Pascual-Pasto
Guillem Pascual-Pasto
GGGrant P. Grothusen
Grant P. Grothusen
YKYannine J. Kalmeijer
Yannine J. Kalmeijer
EKElisavet Kalaitsidou
Elisavet Kalaitsidou
JWJudith Wienke
Judith Wienke
Chimeric antigen receptor (CAR) T-cell therapy is a promising and innovative cancer therapy. However, immunosuppressive tumor microenvironments (TME) limit T cell persistence and durable efficacy. Here, we aimed to identify and target immunosuppressive factors in the TME of neuroblastoma, a pediatric extracranial solid tumor, to improve CAR-T efficacy. Immunosuppressive factors were identified using a multi-omics approach, including single-cell RNA sequencing (scRNA-seq) of 24 neuroblastoma tumors, published bulk-RNA sequencing datasets, and mass-spectrometry of patient-derived tumoroid models. Candidate targets were validated with functional assays in vitro and in vivo. Protein degradation of the top immunosuppressive target by PROTAC technology was used to evaluate the effect on CAR T-cell activity. ScRNA-seq revealed 13 immunosuppressive interactions in the TME of neuroblastoma, two effectors of which, Midkine (MDK) and Macrophage Migration Inhibitory Factor (MIF), were validated as candidate targets across multiple published datasets. Both factors were among the top 6 % of most abundantly secreted factors by patient-derived tumoroid models, substantiating their potential relevance in the TME. In vitro and in vivo functional assays confirmed MIF to be a potent inhibitor of CAR T-cell activation and killing capacity. To translate these findings into a potentially clinically applicable treatment, we explored MIF targeting by PROTAC technology, which significantly enhanced activation of CAR T-cells targeting GPC2 and B7-H3. By defining the immunosuppressive effects of neuroblastoma's TME on CAR T-cell efficacy, revealing the pivotal role of MIF, we provide an analytic pipeline and therapeutic strategy for improving adoptive cell therapies for this pediatric malignancy and potentially other solid tumors.

1 August 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CZChunlong Zhao
Chunlong Zhao
JZJianqiu Zhang
Jianqiu Zhang
HZHangyu Zhou
Hangyu Zhou
RSRita Setroikromo
Rita Setroikromo
GPGerrit J. Poelarends
Gerrit J. Poelarends
Frank DekkerFrank Dekker
Frank Dekker
HDAC8 can mediate signals by using its enzymatic or nonenzymatic functions, which are expected to be critical for various types of cancer. Herein, we employed proteolysis targeting chimera (PROTAC) technology to target the enzymatic as well as the nonenzymatic functions of HDAC8. A potent and selective HDAC8 PROTAC Z16 (CZH-726) with low nanomolar DC50 values in various cell lines was identified. Interestingly, Z16 induced structural maintenance of chromosomes protein 3 (SMC3) hyperacetylation at low concentrations and histone hyperacetylation at high concentrations, which can be explained by HDAC8 degradation and off-target HDAC inhibition, respectively. Notably, Z16 potently inhibited proliferation of various cancer cell lines and the antiproliferative mechanisms proved to be cell-type-dependent, which, to a large extent, is due to off-target HDAC inhibition. In conclusion, we report a hydrazide-based HDAC8 PROTAC Z16, which can be used as a probe to investigate the biological functions of HDAC8.

8 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJosephine Strijker
Josephine Strijker
GPGuillem Pascual-Pasto
Guillem Pascual-Pasto
YKYannine J. Kalmeijer
Yannine J. Kalmeijer
EKElisavet Kalaitsidou
Elisavet Kalaitsidou
CZChunlong Zhao
Chunlong Zhao
JWJudith Wienke
Judith Wienke
While chimeric antigen receptor (CAR) T-cell therapies are showing highly promising first results in neuroblastoma, immunosuppressive tumor microenvironments (TME) limit T cell persistence and durable clinical efficacy. To improve CAR T-cell efficacy further, we applied a multi-omics approach including single-cell RNA sequencing and proteomics, which identified 13 targetable immunosuppressive factors in neuroblastoma. Of these, macrophage migration inhibitory factor (MIF) and midkine (MDK) were validated across multiple published RNA datasets. Moreover, they were secreted in high abundance by neuroblastoma tumoroids. Functional validation experiments revealed MIF as a potent inhibitor of CAR T-cells, in vitro and in vivo. Degradation of MIF by PROTAC technology significantly enhanced CAR T-cell activation targeting GPC2 and B7-H3, providing a potential intervention against MIF. By defining the immunosuppressive effects of neuroblastoma’s TME on CAR T-cell efficacy, particularly the pivotal role of MIF, we provide a therapeutic strategy for improving adoptive cell therapies for this pediatric malignancy.

8 September 2023 in Angewandte Chemie
Verified
Journal Article
Open access
CZChunlong Zhao
Chunlong Zhao
SCShipeng Chen
Shipeng Chen
DCDENG CHEN
DENG CHEN
CRClàudia Río‐Bergé
Clàudia Río‐Bergé
JZJianqiu Zhang
Jianqiu Zhang
Frank DekkerFrank Dekker
Frank Dekker
Macrophage polarization plays a crucial role in inflammatory processes. The histone deacetylase 3 (HDAC3) has a deacetylase‐independent function that can activate pro‐inflammatory gene expression in lipopolysaccharide‐stimulated M1‐like macrophages and cannot be blocked by traditional small‐molecule HDAC3 inhibitors. Here we employed the proteolysis targeting chimera (PROTAC) technology to target the deacetylase‐independent function of HDAC3. We developed a potent and selective HDAC3‐directed PROTAC, P7, which induces nearly complete HDAC3 degradation at low micromolar concentrations in both THP‐1 cells and human primary macrophages. P7 increases the anti‐inflammatory cytokine secretion in THP‐1‐derived M1‐like macrophages. Importantly, P7 decreases the secretion of pro‐inflammatory cytokines in M1‐like macrophages derived from human primary macrophages. This can be explained by the observed inhibition of macrophage polarization from M0‐like into M1‐like macrophage. In conclusion, we demonstrate that the HDAC3‐directed PROTAC P7 has anti‐inflammatory activity and blocks macrophage polarization, demonstrating that this molecular mechanism can be targeted with small molecule therapeutics.